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Multi-component lifestyle interventions are recommended for the weight management of 
adults who are overweight or obese. It is not clear, however, whether delivery individually or 
in groups influences the efficacy. The objective of this research was to systematically review 




The databases MEDLINE, EMBASE, CINAHL, CENTRAL and ISRCTN were searched for 
published and on-going randomised controlled trials (RCTs) from inception to February 2017. 
The reference lists of included studies were also searched. Eligible studies were RCTs 
comparing group against individual lifestyle interventions for weight loss among adults with a 
BMI >25kg/m2. Risk of bias was evaluated using the Cochrane Risk of Bias tool. Heterogeneity 
was investigated using I2 statistics and sub-group analysis. Meta-analysis primarily used fixed 
effects methods and either estimated risk ratios or continuous inverse-variance methods. 
 
Results 
Eight RCTs with 2,139 participants were identified. Group interventions were 62% more likely 
to achieve a 5% weight loss relative to individual interventions (RR 1.62, 95% CI [1.40, 1.86], 
p= <0.00001). Heterogeneity existed (I2 35%, p= 0.15) and was explained through sub-group 
analysis by provider (commercial or non-commercial) (p= 0.004). Relative to individual 
interventions, commercial groups were 89% more likely (RR 1.89, 95% CI [1.58, 2.26], p= 
<0.00001) while results were similar with no significant difference for non-commercial groups 
(RR 1.21, 95% CI [0.95, 1.54], p= 0.11), in achieving a 5% weight loss. Commercial groups 
were marginally more cost-effective (£8,128 per QALY) than non-commercial groups (£8,439 
 
 
per QALY). Neither group nor individual interventions were favoured when measuring efficacy 
by markers of cardiovascular (lipid profile, blood pressure) and diabetes (fasting glucose, 
fasting insulin, HbA1c) disease risk.  
 
Conclusion 
There is a moderate degree of certainty that neither non-commercial groups or individual 
interventions are favoured regarding the likelihood of achieving a 5% weight loss at 1-year. 
There is a high degree of certainty that commercial group participants are more likely to attain 
a 5% weight loss at 1-year, compared to individual intervention participants. Both commercial 
and non-commercial group interventions are cost-effective. Referral to a commercial group 
intervention should be prioritised over a non-commercial group or individual intervention; if the 
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1.0 Introduction  
1.1  Overweight and Obesity 
Overweight and obesity is classified by a Body Mass Index (BMI) of >25kg/m2 and >30kg/m2, 
respectively (World Health Organisation 2014). In England, nearly two-thirds (63%) of adults 
are classified as being overweight or obese according to BMI. Further, obesity is an escalating 
worldwide epidemic. By the year 2030, it is estimated that nearly 58% of the world’s adult 
population could be either overweight or obese (Kelly et al. 2008). 
 
Obesity impacts all facets of an individual’s life. Substantial epidemiologic evidence suggests 
that a BMI >25kg/m2 is a risk factor for mortality and morbidity from a number of co-morbidities; 
including type 2 diabetes, cardiovascular disease, and several cancers (Prospective Studies 
Collaboration et al. 2009) and reduces life expectancy by up to 8 years (Grover et al. 2015). 
Beyond physical health, obesity is associated with a reduced quality of life (Jia and Lubetkin 
2005) and has a negative influence on social (Westermann et al. 2015) and mental well-being 
(National Obesity Observatory 2011). 
 
Excess weight has vast economic consequences on society. In the UK, adults with obesity 
are less likely to be in employment (NICE 2013). Further, those that are in employment have 
more health-related absence and a lesser productivity (NICE 2012); than adults with a healthy 
weight. Consequentially, by combining the cost to healthcare and loss of earnings, overweight 
and obesity is estimated to cost UK society at least £27 billion each year (McKinsey Global 
Institute 2014). 
 
1.2 Lifestyle Interventions  
Obesity is a “complex web” of societal and biological factors which contributes to an individual 
having a dietary intake that is greater than their energy expenditure; resulting in excess 
adiposity (The Government Office for Science 2007). Addressing overweight and obesity 
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poses a significant challenge due to the complexity and interdependency of influencing factors. 
It is expert opinion, therefore, that interventions need take a holistic approach to the 
enablement of lifestyle changes (Gortmaker et al. 2011). 
 
There is strong evidence from several systematic reviews that multi-component lifestyle 
interventions incorporating diet, physical activity and behaviour change leads to greater weight 
loss, as opposed to physical activity intervention alone (Johns et al. 2014, Greaves et al. 2011, 
Kirk et al. 2012). Combined behavioural interventions are effective in inducing a weight loss 
of 5 to 10% (Johns et al. 2014). For this reason, multi-component lifestyle interventions that 
include behaviour change strategies to increase physical activity, improve eating behaviour 
and reduce energy intake are the first-line interventions for adults overweight and obesity 
(NICE 2014a). 
 
Drop-out rates from lifestyle interventions have been reported to be as high as 77% (Finley et 
al. 2007). Attrition is a consistent and strong predictor of weight loss (Ali et al. 2012) and is 
considered a surrogate to behavioural adherence. Lesser adherence to weight management 
behaviours means that lifestyle induced weight loss has a trajectory to diminish over time and 
can lead to weight re-gain (Butryn et al. 2011). For this reason, a 5 to 10% weight loss should 
be maintained for more than 12 months to be considered a clinically meaningful and 
maintained weight loss (Stevens et al. 2006). 
 
1.3 Social Support and Weight Management 
Network phenomena suggest that social influences are a factor in the obesity epidemic. It has 
been proposed that this phenomenon can be harnessed, and that the provision and promotion 
of positive social support can be used to intervene (Christakis and Fowler 2007). Thoits (1995) 
delineates social support as a coping resource when handling “stressors”. Social support 
functions to provide emotional, informational, problem-solving (Thoits 2011) and 




Social support is positively correlated with weight maintenance after weight loss (Elfhag and 
Rossner 2005); and is an integral cognitive behavioural approach for weight management. 
This is a hierarchical behavioural change taxonomy of CALOR-E, whereby social support 
provision assists individuals in changing their physical activity and eating behaviours (Michie 
et al. 2013). In turn, this provision paticipants to re-enact specific food and activity behaviours, 
as outlined within OxFAB taxonomy (Hartmann-Boyce et al. 2016). These include ‘buddying 
support’, ‘motivational support’ and ‘imitation modelling’ behaviours.  
 
1.3.1 Group Interventions 
In relation to weight management, a participant’s peers are those who are, alongside, also 
actively engaged with the weight management programme. Reports suggest that social 
support, empathy, role modelling, accountability and problem solving are offered in group 
settings by peers and are important factors for lifestyle change and weight loss (Hayaki and 
Brownell 1996, Latner et al. 2006). 
 
Based on social-cognitive theory (Bandura 1997), group-based lifestyle interventions 
capitalise upon participant interactions to promote self-efficacy for behaviour change and thus 
the attainment of weight loss (Palmeira et al. 2007). Provision of a genuine feeling of 
empathetic understanding normalises the challenges of weight management and validates 
participants’ concerns and feelings. Perceived autonomous support from peers is associated 
with greater motivation, manifesting in increased physical activity and healthier eating 
behaviours (Ng et al. 2014). 
 
1.3.2 Interventionist 
Interventionists for individual and non-commercial group weight management programmes 
tend to be healthcare professionals, who draw from their collective professional experience to 
help participants and rely on the provision of informational support. Autonomous support from 
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healthcare professionals has been shown to predict self-regulation and subsequent 
sustainment of long-term weight loss (Williams et al. 1996). 
 
Healthcare professionals have, until more recently, been the predominant care giver for weight 
management interventions. However, participants have expressed concern over a perceived 
lack of sensitivity and understanding from healthcare professionals (Phelan et al. 2015). It has 
also been highlighted that healthcare professionals have weaker social ties with service users, 
in comparison with social ties with peers or mentors (Verheijden et al. 2005). It has therefore 
been put forward that mentor support from lay interventionists may be more effective for weight 
management (Verheijden et al. 2005). 
 
Commercial weight loss programmes, such as Weight Watchers and Slimming World, recruit 
‘successful’ alumni to lead local programmes; without the requirement for them to have any 
formal healthcare education. Such coaches are perceived by service users to be more familiar 
and more accessible (Leahey and Wing 2013). They build trust with service users by sharing 
their lived experiences, which envisions a desired self in the service user’s own future (Markus 
and Nurius 1986); motivating them towards this goal. In this sense, lay interventionists can 
serve as aspirational role models for participants (Thoits 2011). 
 
1.4  Existing Literature    
Systematic reviews have investigated the efficacy of lifestyle interventions in relation to a 
primary outcome of weight loss. While similar research exists, the vast majority of current 
research is not congruent to my own research question. The foci of others’ research have 
been the comparison of active interventions against minimal intervention controls, or have 
combined group and individual interventions together (Peirson et al. 2014, Hassan et al. 2016, 




There is, however, some in-direct evidence from Hartmann-Boyce et al. (2014a, 2014b) on 
the efficacy of interventional components, such as delivery to groups or to individuals. Based 
on synthesised evidence from RCTs published up to the year 2012, Hartmann-Boyce and 
colleagues examined efficacy in relation to weight loss. They found that neither group nor 
individual interventions were associated with weight loss at 1-year. However, the limitation of 
in-direct evidence is that the results should be interpreted with caution due to the loss of power 
from randomisation. 
 
A single systematic review exists that does provide direct evidence for the effectiveness of 
group and individual interventions. This study, authored by Paul-Ebhohimhen and Avenell 
(2009), provides evidence from RCT studies that group interventions are more effective than 
individual interventions, as measured by weight loss alone, over 1-year of follow-up. These 
findings, although directly pooled, are limited in reliability and generalisability owing to the 
included studies dating back to the pre-1990s.   
 
Current guidelines, (NICE 2014a, 2014b), have been formed based upon the availability of 
existing quality literature at the time of publication. They offer a brief recommendation that 
group interventions should be favoured over individual programmes on the basis that these 
may be more cost-effective. This recommendation is based on their virtual economic modelling 
and was not formed from direct clinical evidence. NICE (2014a) acknowledge that further 
research is needed to examine the influence of the components of lifestyle programmes on 
adherence, effectiveness and cost-effectiveness. In particular, NICE (2014a) makes reference 
to the need for further research to explore the specific components of interventions, including: 
the interventionist (healthcare professionals versus lay persons), the delivery (individual- 




1.5 Rationale  
Current guidance (NICE 2014a, 2014b) on lifestyle programme delivery for weight 
management is brief and self-admittedly requires further investigation. Periodic evidence 
synthesis is fundamental in order to update and inform planning on how best to deliver cost-
effective health services and outcomes for overweight and obesity.  
 
In the treatment of overweight and obesity, group interventions that offer social support 
networks may be the foundation to behaviour change for weight management. However, in 
the absence of any recent evidence synthesis in this area, it is unclear whether group 
interventions or individual interventions are most effective.  
 
Thus, in the context of existing research in the field, this research provides updated knowledge 
on the effectiveness of group compared to individual interventions; as measured by weight 
loss. Further, this research offers a more holistic analysis of efficacy, extending measurement 
to include patient-reported outcome measures, adverse events, cost-effectiveness and clinical 
markers of cardiovascular and diabetes disease risk.  
 
1.6 Aims and Objectives  
The aim of this systematic review is to establish the effectiveness of group relative to individual 
lifestyle interventions for the treatment of overweight and obesity in adulthood.  
 
The objectives are to: 
(1) Identify relevant RCT studies for inclusion 
(2) Critically appraise the methodological quality of included studies 
(3) Synthesise data from included studies  
(4) Establish the certainty of the evidence using GRADE 
(5) Discuss recommendations for clinical practice 
(6) Identify priorities for further research 
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2.0 Methodology  
 
2.1 Study Identification 
2.1.1 Eligibility Criteria 
The review question was framed in terms of the population (P), intervention (I), comparator 
(C), outcomes (O) and study design (S) (NHS Centre for Reviews and Dissemination 2009) 
and is detailed in Table 1.  
 
The review question then informed the inclusion and exclusion criteria; which are outlined in 
Table 2. These eligibility criteria were pre-defined and published (Abbott, S. and Bryant 2017) 
prior to carrying out the literature search. The eligibility criteria were detailed explicitly, in order 
to minimise researcher bias in the screening stages.  
 





Adults (>18 years old) 
















Randomised Controlled Trials (RCTs) 
 
 
2.1.2 Literature Search 
Literature searches were made using Medical Subject headings (MeSH) or keywords relevant 
to the framed question of this review. The search strategy was developed and piloted in 
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consultation with a medical librarian. This was tested and refined in order to achieve the 
maximum sensitivity for obtaining relevant studies, using an evidence based approach 
recommended by the Cochrane Collaboration (Glanville et al. 2006). The terms used and how 
these were combined are detailed in Appendix 1.  
 
A systematic search was conducted using the search strategy on the 9th February 2017. 
MEDLINE (1946 to present), EMBASE (1974 to present) and CINAHL (1981 to present) were 
searched via EBSCO Host and the CENTRAL database was searched via The Cochrane 
Library. The ISRCTN database was searched to identify any research that may not have been 
published. To ensure all relevant literature was captured, the reference lists of the included 







Table 2: Inclusion and Exclusion Criteria 
 
 Inclusion Exclusion 
Population ● Inclusion BMI ≥25kg/m2 
● ≥ 18 years old 
● Inclusion BMI <25kg/m2 
● <18 years old 
● Pregnancy  
Intervention ● Group/Group + Individual  
● Promoting weight loss  
● Multi-component programmes 
● Non-specific disease management  
● Lifestyle intervention only 
● Individual only 
● Promoting weight maintenance  
● Single component programmes 
● Disease-specific management 
● Surgical, drugs, meal replacements  
Comparator ● Individual contact  
● Active intervention 
● Any group contact 
● Minimal intervention/control 
Outcome ● Weight change at 1-year ● Weight change not reported at 1-year 
Setting ● Outpatient, primary care, community  
● Any country 
● Inpatients  
● No restriction on country 
Design  ● RCT ● Any other study design 
Literature ● Any publication type 
● Any year 
● No exclusion on publication type 
● No exclusion on publication year 
Language ● Any language ● No language restriction 
 
 
2.1.3 Screening Process  
2.1.3.1 Titles and Abstract 
Two independent reviewers electronically screened all search results for possible inclusion 
based on title and abstract, using EPPI-Reviewer 4 software. Each reviewer was blinded to 
the other’s decisions until the point of arbitration. Any discrepancies were reviewed by 
consensus and overseen by a third review author as arbitrator. Search results proceeded to 
be screened using a full-text assessment when both reviewers were in agreement that the 
inclusion criteria were met. If there was insufficient detail in the title and abstract, the article 





Full-text documents were obtained and uploaded electronically onto the EPPI-Reviewer 4 
software. Two independent reviewers screened all articles that had progressed to the full-text 
screening stage. Screening decisions were recorded electronically and each reviewer was 
blinded to the other’s decisions. Reasons for exclusion were given a priori by each reviewer. 
Reasons for exclusion were, in order, as follows: ‘population’, ‘intervention’, ‘comparator’, 
‘outcome’, ‘follow-up period’ and ‘study design’.  
 
Any discrepancies during the screening of full-texts were discussed between reviewers to 
reach a consensus. If a consensus was not agreed, a third independent reviewer was involved 
in arbitration and made the final decision on inclusion.  
 
If there was insufficient detail reported in the full-text, the authors were contacted to extract 
more information. If the authors did not respond to communication within four weeks, the study 
was presumed ineligible and was excluded under ‘inconclusive’. Likewise, articles were 
excluded under ‘study ongoing’ if authors responded but stated that the data had not yet been 
analysed.  
 
2.2 Data Collection 
2.2.1 Data Items 
Data was independently extracted by one reviewer, using full-text copies of the included 
articles. A second author checked the extracted data for any discrepancies (Higgins and 
Green 2011) Data was extracted onto an electronic version of the ‘Good Practice Data 
Extraction Form’ (Cochrane Effective Practice and Organisation of Care 2017) – as shown in 
Appendix 2. Descriptive information was extracted about the characteristics of each study (e.g. 
inclusion criteria, participants, study setting, details of the intervention and comparator etc.) to 
assess for between-study heterogeneity.  
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Quantitative outcome data was extracted for the primary and secondary outcomes; as detailed 
below (Table 3), To ensure transparent outcome reporting, all obtainable outcome measures 
were detailed in a matrix table according to ORBIT classification (Kirkham et al. 2010). Further 
data was sought and obtained by contacting an author (Jebb et al. 2011). Both of these steps 
were taken to minimise selective reporting bias within this review.  
 
Table 3: Primary and Secondary Outcome Measures 
Outcome Data Type Measure Time-point 
Primary outcome 













Attainment of 5% weight loss 
 
Programme-end 
Physical activity level Continuous IPAQ 1-year, programme-end 
Dietary intake Continuous Macronutrient composition 1-year, programme-end 
Cardiovascular disease risk Continuous Blood pressure, lipid profile 1-year, programme-end 
Diabetes risk Continuous HbA1c, fasting glucose, fasting insulin 1-year, programme-end 
Quality of life Continuous EQ-5D 1-year, programme-end 
Social support$ $data not attainable 
Mental health Continuous  1-year, programme-end 
Cost-effectiveness Binary Cost per QALY gained  1-year 
Attrition Binary Attendance  1-year, programme-end 
Risks Binary Related adverse events 1-year 
 
2.2.2 Summary Measures 
2.2.2.1 Binary Data  
Data was extracted as a standard estimation of the risk ratio (RR) and its 95% confidence 
interval (CI) using frequency data from binary 2x2 tables. RR is a relative effect measure and 
is known to be more consistent than absolute measures for meta-analysis (Deeks 2002). The 
RR is defined as the likelihood of exposure to an event (i.e. achievement of 5% weight loss) 
relative to those without exposure to event (i.e. did not achieve 5% weight loss). It is not 
possible to calculate RR where there is a zero exposure to an event (i.e. adverse events) 





2.2.2.2 Continuous Data  
The majority of the continuous data for outcome measurement that was extracted was 
obtained using the same instrument and scale. In these instances, data was extracted as 
mean, standard deviation (SD), and the number of participants whom contributed data. Where 
SD were not presented, these were calculated from standard errors (SEs) using the following 
formula: SD = SE x √n. 
 
While physical activity was measured using the same instrument (IPAQ), the scale varied 
between studies and thus did not yield comparable data. In order to utilise this data, data was 
extracted in the same way but was then calculated to an effect size measure using the 
standardised mean difference (SMD). The limitations of this method are considered and it is 
acknowledged that SMD is difficult to interpret; given that it is reported in units of standard 
deviation (Higgins and Green 2011) rather than familiar units. 
 
2.2.3 Missing Data and Imputations 
High drop-out rates are inherent within RCTs of obesity interventions (Elobeid et al. 2009). It 
is assumed to be because of those participants who lose less weight being more reluctant to 
be followed up. Imputation methods are often used for missing data; such as ‘baseline 
observation carried forward’ (BOCF) or ‘non-responder imputation’ (NRI). BOCF uses the 
baseline observation, in place of the missing outcome. In the context of weight loss studies, 
BOCF requires the assumption that all participants who dropped out of the study returned 
exactly to their baseline weight (Cresswell and Mander 2014). NRI, on the other hand, 
attributes participant non-attendance with a lack of efficacy (Dossing et al. 2014).  
 
When handling dichotomous outcomes, such as attaining 5% weight loss, we used NRI in the 
assumption that non-attendance meant a non-achievement of a 5% weight loss. However, the 
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same is not possible for continuous outcomes. Further, not all included studies in this review 
used imputations for their missing data and instead reported data for “completers-only”.  
 
We therefore extracted data with a priori preference to BOCF, because it mitigates the bias 
associated with drop-out rates by assuming a zero weight loss, but also included extracted 
completers-only data where this was not available.  
 
2.2.4 Studies with Multiple Treatment Groups 
Some of the included studies contributed more than one intervention group to the meta-
analyses. To overcome unit-of-analysis error, we formed intervention groups with pair-wise 
comparisons, as recommended by Cochrane methods (Higgins and Green 2011). For 
dichotomous outcomes, the sample sizes and number of events were summed across groups. 
For continuous outcomes, means and standard deviations were combined using the formulae 
outlined in Appendix 4.  
 
Data was extracted separately for each intervention (i.e. group) while the comparator 
interventions (individual) were combined, where applicable. Once combined, the comparator 
group was split equally to avoid double counting the pooled results (Higgins and Green 2011).  
 
2.2.5 Risk of Bias Assessment (Individual Studies) 
Risk of bias was assessed in accordance with Cochrane guidelines and used an adapted 
version of the Cochrane Risk of Bias Tool (Higgins et al. 2011). This was adapted by removing 
the ‘blinding of participants and personnel’ item. This was removed because it is not feasible 
to blind interventionists and participants to lifestyle interventions. 
 
Included studies were assessed independently by two reviewers for risk of bias. Any 
disagreements were resolved by discussion between reviewers and if necessary, involved 
arbitration by the third reviewer. Both reviewers independently assigned judgement of high, 
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low or unclear risk for each item for all included studies, along with a free text justification (as 
shown in Appendix 3).  
 
For the purpose of this systematic review, it was judged that the key domains that could 
influence the integrity of the results were ‘incomplete outcome data’, ‘random sequence 
generation’ and ‘allocation concealment’. Therefore, when assigning an overall risk of bias for 
each study, all three items must have been judged to be ‘low’ risk for a study to be judged to 
have a ‘low’ risk of bias overall. If any of these three items are judged to have an ‘unclear’ or 
‘high’ risk of bias; the study was classified as having an ‘unclear/high’ risk of bias. This overall 
classification of a study’s risk of bias was then utilised as part of GRADE assessment, and for 
the pre-defined sensitivity analyses. 
 
2.3 Data Synthesis  
The data synthesis methodology was pre-defined in the protocol (Abbott and Bryant 2017). 
This ensured that post-hoc analyses were not performed, therefore avoiding the induction of 
biases associated with selective reporting of only statistically significant results.  
 
2.3.1 Heterogeneity  
A visual test for heterogeneity was used to assess the overlap in confidence intervals for each 
effect estimate on a forest plot. If the overlap was poor or there were outliers, a test for 
statistical heterogeneity was performed. Statistical assessment of heterogeneity used the I2 
method alongside the Chi2 p-value. I2 provides an estimate of the percentage of inconsistency 
thought not to be due to chance. Substantial statistical heterogeneity was defined as an I2 of 






Meta-analysis was undertaken for each outcome where data had been extracted from a 
minimum of 2 studies (Valentine et al., 2010) using RevMan 5 software.  
 
Fixed-effects meta-analysis, using Mantel-Haenszel methods (Mantel and Haenszel 1959) 
was used when the observed differences among study results were solely due to chance; i.e. 
where substantial statistical heterogeneity was not identified, or where heterogeneity was 
explained by sub-group analysis.  
 
Meanwhile, random-effects meta-analysis, using DerSimonian and Laird methods, 
(DerSimonian and Laird 1986), was used to incorporate heterogeneity among studies, only 
when heterogeneity was un-explained by sub-group analysis (Higgins and Green 2011). 
 
A narrative approach was taken instead, if data was obtainable for only one included study or 
if substantial heterogeneity was found (see 2.3.1).  Narrative synthesises explored within and 
between-study results in line with the guidance from the Centre for Reviews and Dissemination 
(2009). 
 
2.3.3 Meta-biases  
Testing for publication bias using funnel plot asymmetry was not appropriate given that there 
were only 8 studies included in the review. This meant that the test power would be too low to 
distinguish chance from genuine asymmetry (Sterne et al. 2011). Publication bias was instead 
explored descriptively and according to classification of sample size (Easterbrook et al. 1991). 
For this exploration, the pre-specified primary outcome for each included study was used to 
assess for bias in publication according to the significance (p= <0.05) of results. 
 
Larger studies in this review were conducted with greater methodological rigor. Further, only 
one small study was included in this review (Long et al. 1983). This singular study contributed 
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a very low weighting to the fixed-effects meta-analysis and only had usable data for one 
secondary outcome alone (see 3.5.10). Based on this, small-study effects are unlikely to have 
influenced the results (Higgins and Green 2011). 
 
2.3.4 Confidence in Cumulative Evidence 
Six outcomes were identified as being the most important outcome measures for patient-care 
and decision making, and are outlined in Table 4.  
 
The GRADE approach (Schünemann et al. 2008) was used to interpret findings on the basis 
of evidence certainty.  Each outcome was assessed against the following domains: risk of 
bias, inconsistency, imprecision, indirectness and publication bias. GRADEPRO was used to 
create a summary of findings table, which also communicated the magnitude and sum of the 
absolute effect of the interventions included in the review. We presented these absolute effects 
using baseline risk, risk difference and the number needed-to-treat (NNT) for a beneficial 
outcome. Communicating absolute effects is important in the interpretation of meta-analysis 















Table 4: Rationale for Inclusion of GRADE Outcomes 
Outcome Rationale 
Achievement of 5% weight loss Objective clinical measure: internationally accepted target which 
demonstrates health improvements (Jensen et al. 2014, NICE 2014a) 
Systolic blood pressure Objective clinical measure: continuous marker of cardiovascular 
disease risk (World Health Organisation 2002, NICE 2011) 
Total:HDL cholesterol Objective clinical measure: measure of both total and HDL cholesterol 
is recommended by (NICE 2016) as the best measure of CVD risk  
HbA1c Objective clinical measure: reflects long-term glycaemic exposure 
(World Health Organisation 2011) 
Quality of Life Patient reported outcome measure: emotional and psychological 
assessment of well-being (Janse et al. 2004) 
Cost-effectiveness Health economics measure: assessment of whether the intervention 
provides significant benefit at an acceptable cost (Appleby et al. 2007) 
 
2.4 Pre-Specified Additional Analyses 
Sensitivity analyses were performed by excluding studies which were judged to have an 
‘unclear’ or ‘high’ risk of bias, see 2.3.5. These were undertaken to determine whether the 
results were affected by study quality. Where results were not altered by sensitivity analysis, 
the results of the studies, regardless of risk of bias, can still be regarded with a degree of 
certainty. If, conversely, results were affected by the sensitivity analysis; the original analysis 
of all included studies will be interpreted with caution. Instead, results obtained from the 
analysis of only ‘low’ risk of bias studies will have more credibility.  
 
The primary outcome had a near statistically substantial heterogeneity. As was pre-specified 
in the protocol, sub-group analysis was therefore performed to explain this. Study 
characteristics were inspected to identify potential methodological or clinical heterogeneity. 
Sub-group analysis by the intervention provider (categorised as being commercial or non-
commercial) explained heterogeneity entirely for the primary outcome. Thus, this sub-group 
analysis was then also performed on the meta-analyses of the secondary outcomes.
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3.0 Results  
3.1 Study Selection 
The study selection process is detailed in Figure 1. A total of 8 studies were identified for 
inclusion in the review. These were generated from a search of the databases MEDLINE, 
CINAHL, EMBASE, CENTRAL and ISRCTN, which retrieved a total of 5,856 citations. 
Importing the reference lists of the 8 included studies and the relevant systematic review by 
Paul-Ebhohimhen and Avenell (2009) provided an additional 485 citations. After adjusting for 
duplicates, the citations identified in the literature search totalled 5,673. Of those, 5,467 
citations were discarded after screening their titles and abstracts as they did not meet the 
inclusion criteria. The full texts of the remaining 206 citations were then examined in further 
detail.  
 
After examination of the full-text, 198 citations were excluded because they did not meet the 
inclusion criteria. The reasons for excluding studies are given in detail in Figure 1. An 
inappropriate comparator was the main reason for exclusion of full-text articles (n= 104, 
50.4%), usually because the comparator was a minimal intervention or control, or involved 
group-delivery. Other reasons for exclusion were study design (before-after studies or 
secondary analyses), population (entry BMI unspecified or including participants with a BMI 
<25kg/m2) and intervention (involving pharmacological, VLCD or surgical interventions; or 






Figure 1: PRISMA Flowchart 
Reproduced from Moher et al. (2009) 
 
Some materials have been removed due to 3rd party copyright. The unabridged version can be 
viewed in Lancester Library - Coventry University.
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3.2 Study Characteristics  
3.2.1 Participants 
A combined total of 2,139 overweight or obese adult participants were included in this review 
overall (refer to Table 2). The number of participants in each study ranged from 36 to 779. All 
the studies included were conducted in westernised countries; of which 50% were conducted 
within UK populations. Seven of the 8 studies included both male and female participants, 
while one study by Long et al. (1983) included only females. The majority (75%) of studies 
reflected a mean age of between 45 to 50 years old.  
 
Inclusion BMI criteria across studies varied considerably. Five studies included participants 
who were overweight or obese (>25kg/m2 to >28kg/m2); while the remaining studies included 
only participants who were classified as obese (>30kg/m2 to >40kg/m2). Despite the inclusion 
criteria being accessible to participants who were classified as overweight, the mean BMI for 
all studies was >30kg/m2, and thus obese according to BMI classification.  
 
3.2.2 Contact Time 
The duration of study follow-up was 12 or 24 months; but the majority (75%) ran for 12 months. 
In all of the group interventions, the intensive initial phase consisted of weekly sessions, 
whereas only half of individual interventions were delivered weekly. Where stated, the total 
contact time for a participant in the group intervention was greater (12 – 55.3 hours) than for 
a participant in the individual intervention (2.5 – 11 hours).  
 
3.2.3 Setting 
Out of the 12 group interventions, most (n= 5) were performed in the commercial slimming 
club setting and the least were performed in primary care (n= 1) and in the community setting 
(n= 1). Out of the 9 comparator arms, most were conducted in the primary care (n= 3) and 
out-patient (n= 3) settings. All the group interventions were delivered in-person; whereas one 
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Among the group interventions, more non-healthcare professionals (5 commercial Slimming 
Club Leaders, 1 Food Advisor, 1 Weight Loss Coach) than healthcare professionals (1 
Psychologist, 1 Specialist Nurse, 2 Dietitians, 1 Joint Dietitian/Psychologist) delivered the 
intervention. Notably, 1 of these interventions was provided through Slimming World (Jolly et 
al. 2011) and 3 interventions were provided by Weight Watchers (Jolly et al. 2011, Heshka et 
al. 2003, Jebb et al. 2011). These two commercial programmes are exclusively led by prior 
members who have been “successful” with weight loss.  
 
For the individual interventions, nearly all interventionists were healthcare professionals (3 
Primary Care Nurses/GPs, 1 Pharmacist, 3 Dietitians, 1 Dietitian & Endocrinologist) and one 
interventionist was a non-healthcare professional (Weight Loss Coach). 
 
3.2.5 Behavioural Taxonomies  
The underpinning behavioural components were described in sufficient detail to assign 
clustered behavioural taxonomies (Michie et al. 2013) to 83% (n= 10) of the intervention arms 
and to 67% (n= 6) of comparator arms. The group interventions utilised between 5 and 13 
different taxonomies and the individual interventions utilised between 4 and 8 different 
taxonomies. Across both group and individual interventions, the most frequently utilised 
taxonomies were Goals and planning (100%), Feedback and monitoring (100%) and 
Comparison of outcomes (100%). In addition, 100% of group interventions utilised Social 












































o Primary care setting 
o Delivered in-person + remote telephone/email 
o 24 months duration: weekly (0-3 months), 
monthly (4-6months), bi-monthly (7-
24months) 
o 55.3hrs contact time 
o Behavioural taxonomies 1,3,8,9,10,15 
Weight Loss 
Coach 
o Remote setting 
o Delivered remotely telephone/email 
o 24 months duration: weekly (0-3 
months), monthly (4-6months), bi-
monthly (7-24months) 
o 11hrs contact time 



























o Hospital outservice user setting 
o Delivered in-person 
o 12 months duration: weekly (0-1.5 months), 
monthly (2-6 months), once (12 months) 
o 14hrs contact time 
o Behavioural taxonomies 1,3,6,8,9,10,13,15 
Dietitian 
o Hospital outservice user setting 
o Delivered in-person 
o 7.5 months duration: weekly (0-2 
months), monthly (3-6 months), once (12 
months) 
o Contact time not stated 































o ‘Slimming club’ setting 
o Delivered in-person 
o 24 months duration: weekly (0-3 months), bi-
annually (4-24 months) 
o Contact time not stated 
o Behavioural taxonomies 1,2,3,8,9,11,12,13,14,15 
Dietitian 
o Setting not stated 
o Delivered in-person 
o 24 months duration: twice (0-3 months), 
bi-annually (4-24 months) 
o 2.5hrs contact time 






























o ‘Slimming club’ setting 
o Delivered in-person 
o 12 months duration: weekly (0-12 months) 
o Contact time not stated 
o Behavioural taxonomies 1,2,3,8,9,11,12,13,14,15 
Nurse or GP 
o Primary care setting 
o Delivered in-person 
o 12 months duration: monthly (0-12 
months) 
o Contact time not stated 




































o ‘Slimming club’ setting 
o Delivered in-person 
o 12 months duration: weekly (0-3 months), 
once (12 months) 
o 12hrs contact time 




o Pharmacy setting 
o Delivered in-person 
o 12 months duration: weekly (0-3 
months), once (12 months) 
o 3.75hrs contact time 


















o ‘Slimming club’ setting 
o Delivered in-person 
o 12 months duration: weekly (0-3 months), 
once (12 months) 
o 18hrs contact time 
o Behavioural taxonomies 1,2,3,5,6,8,9,11,14,15 
Primary Care 
Nurse 
o Primary care setting 
o Delivered in-person 
o 12 months duration: weekly (0-3 
months), once (12 months) 
o 3.75hrs contact time 
o Behavioural taxonomies 1,2,3,8,9,11,14,15 
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o Slimming club’ setting 
o Delivered in-person 
o 12 months duration: weekly (0-3 months), 
once (12 months) 
o 18hrs contact time 
Behavioural taxonomies 1,2,8,9,10.11.12.13.14,15 
 
Food Advisor 
o Community setting 
o Delivered in-person 
o 12 months duration: weekly (0-1.5 months), 
once (12 months) 
o 12hrs contact time 

































o Hospital outservice user setting 
o Delivered in-person 
o 12 months duration: weekly (0-4 months), 
quarterly (6-12 months) 
o 14hrs contact time 
o Behavioural taxonomies not described 
Dietitian o Hospital outservice user setting 
o Delivered in-person 
o 12 months duration: weekly (0-4 
months), quarterly (6-12 months) 
o 5.5hrs contact time 





















o Hospital outservice user setting 
o Delivered in-person 
o 12 months duration: weekly (0-4 months), 
quarterly (6-12 months) 
o 20hrs contact time 



















o Primary care setting 
o Delivered in-person 
o 12 months duration: weekly (0-2 months), 
monthly (3-12 months) 
o 18hrs contact time 
o Behavioural taxonomies 1,2,3,4,5,6, 8,9,10,11,12,14,15 
Primary Care 
Nurse 
o Primary care setting 
o Delivered in-person 
o 12 months duration: fortnightly (0-2 
months), bi-annually (6-12 months) 
o 3hrs contact time 































o Hospital outservice user setting 
o Delivered in-person 
o 12 months duration: weekly (0-3 months), bi-
weekly (4-12 months) 
o 46.5hrs contact time 




o Hospital outservice user setting 
o Delivered in person 
o 12 months duration: pragmatic (0-12 
months) 
o Contact time not stated 













Behavioural taxonomies: 1Goals and planning, 2Reward and threat, 3Regulation, 4Antecedents, 5Identity, 6Self-belief, 7Covert learning, 8Feedback and monitoring, 9Social support, 10Shaping knowledge, 11Natural 
consequences, 12Comparison of behaviour, 13Associations, 14Repetition and substitution, 15Comparison of outcomes, 16Scheduled consequence 
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3.3 Risk of Bias within Studies  
The risk of bias across the domains within each study shows variation in the quality of the 
included studies (Figure 2). McRobbie et al. (2016) was at ‘low’ risk of bias across all domains. 
Conversely, Long et al. (1983) and Tur et al. (2013) had no domains considered to be at ‘low’ 
risk of bias.  
 
An assessment of the overall risk of bias of individual studies classified four studies with a 
‘low’ risk of bias (McRobbie et al. 2016, Jebb et al. 2011, Jolly et al. 2011, Appel et al. 2011), 
one study with an ‘unclear’ risk of bias (Heshka et al. 2003) and three studies with a ‘high’ risk 
of bias (Long et al. 1983, Ash et al. 2006, Tur et al. 2013). 
  



















3.4  Outcomes reported in Individual Studies 
The outcome matrix, as shown in Figure 3, illustrates outcome reporting for individual studies 
at the 1-year follow-up programme-end time points.  
 
3.4.1  1-year follow-up 
Weight change was stated as the primary outcome of measure across all studies. Despite 
weight change being reported in kilograms in all eight studies, weight change as a proportion 
(%) was reported in only 5 of these studies (Appel et al. 2011, Heshka et al. 2003, Jebb et al. 
2011, Jolly et al. 2011, McRobbie et al. 2016). The most consistently reported outcome was 
attrition, whereby data was provided for all eight studies. Other than the outcomes of weight 
change and attrition, the outcomes reported by individual studies varied considerably.  
 
Adverse events were reported by half (n= 4) of studies (Appel et al. 2011, Heshka et al. 2003, 
Jebb et al. 2011, McRobbie et al. 2016). Some outcomes were reported by only one study 
each including; dietary intake (Jebb et al. 2011), and quality of life and mental health (Appel 
et al. 2011). Data on quality of life was collected by a further two studies (McRobbie et al. 2016 
and Jebb et al. 2011), but was presented only as part of cost-effectiveness analyses and thus 
extraction was not possible. Data was not reported by any study for the outcome of social 
support. 
 
For cardiovascular outcomes, biochemical markers of lipid profiles were recorded for half (n= 
4) of studies (Appel et al. 2011, Heshka et al. 2003, Jebb et al. 2011, Tur et al. 2013); although 
the markers measured varied by individual study (see Figure 3). Meanwhile, systolic and 
diastolic blood pressure readings were reported by 63% (n= 5) of studies (Appel et al. 2011, 






























































































































































































































































         1-year follow-up 
Appel (2011) ✔ ✔ ✔ ✔ ✘ ✘ ✘ ✔ ✔ ✔ ✔ ✔ ✘ ✔ ✔ ✘ ✘ ✔ ✔ ✘ 
Heshka (2003) ✔ o1  ✔ ✘ ✘ ✘ ✘ ✘ ✔ ✔ ✔ ✘ ✔ ✔ ✔ ✔ ✘ ✔ ✔ ✘ 
Jebb (2011) ✔ o1  ✔ o2 ✔ ✔ ✘ ✘ ✔ ✔ ✘ ✘ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Jolly (2011) ✔ o1  ✔ ✘  ✘ ✔ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✔ ✘ ✘  
McRobbie (2016) ✔ o1  ✔ o2  ✘ ✔  ✘ ✘ ✔ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✔  ✔  ✔ 
Ash (2006) ✔ o1  o1  ✘ ✘ ✔3 ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✔ ✘ ✘ 
Long (1983) o4 o1  o1  ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✔ ✘ ✘ 




Appel (2011) ✔ N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Heshka (2003) ✔ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✔ N/A N/A 
Jebb (2011) ✔ N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Jolly (2011) ✔ o1  ✔ ✘ ✘ ✔ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✔ N/A N/A  
McRobbie (2016) ✔ o1  ✔ ✘ ✘ ✔  ✘ ✘ ✔ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✔  N/A N/A 
Ash (2006) ✔ ✘ ✘ ✘ ✘ ✔3 ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✔ N/A N/A 
Long (1983) o5 ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✘ ✔ N/A N/A 
Tur (2013) ✔ N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
✔ indicates fully reported results; o indicates partially reported; ✘ indicates not reported 
1 weight reported in kg, 2reported only within cost-effectiveness analysis, 3non-validated arbitrary scoring, 4unable to calculate SD, 5reported as median
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At least one marker of diabetes risk was measured for half (n= 4) of studies; of which all 
reported on fasting glucose (Appel et al. 2011, Heshka et al. 2003, Jebb et al. 2011, Tur et al. 
2013). Two of these studies each reported on fasting insulin (Heshka et al. 2003, Jebb et al. 
2011) and HbA1c (Jebb et al. 2011, Tur et al. 2013).  
 
Physical activity was measured by four studies (Jebb et al. 2011, Jolly et al. 2011, McRobbie 
et al. 2016, Ash et al. 2006); all of which used the IPAQ questionnaire for measurement. 
However, Ash et al. (2006) used a non-validated arbitrary measurement of being ‘sufficiently 
active’ which was subjective to the authors and thus was not extracted. The three remaining 
studies reported through validated methods of scoring and the reporting units varied across 
mins/week, kcals/week, sitting time/week and MET-mins/week. 
 
3.4.2 Programme-end 
For three studies, Jebb et al. (2011), Tur et al. (2013) and Appel et al. (2011), programme-end 
outcome measurements were not applicable because these interventions were administered 
over the entire 1-year period. The five remaining studies (Heshka et al. 2003, Jolly et al. 2011, 
Long et al. 1983, Ash et al. 2006) all reported on attrition at programme-end. Of these five 
studies, only McRobbie et al. (2016) and Jolly et al. (2011) reported further on clinical 
outcomes. Both studies reported on proportion of participants achieving greater than 5% 
weight loss and physical activity level change, while McRobbie et al. (2016) in addition 
reported on blood pressure changes. 
 
3.5 Meta-Analysis of Results 
The findings of this review are based upon 12 group interventions across 8 RCTs. Five group 
interventions were commercial (888 participants), 7 were non-commercial (605 participants) 




3.5.1 Weight Loss 
The likelihood of achieving 5% weight loss was analysed in 5 studies at the 1-year follow-up 
time-point (Figure 4). Results showed that participants of group interventions were 62% more 
likely to attain 5% weight loss at 1-year (RR 1.62, 95% CI [1.40, 1.86], p= <0.00001) relative 
to individual interventions.  Some heterogeneity remained and was dealt with by sub-group 
analysis. There was a significant difference between the non-commercial and commercial 
group analyses (p= 0.004) (Figure 4). 
 




Attendees of commercial group interventions were 89% more likely to achieve 5% weight loss 
(RR 1.89, 95% CI [1.58, 2.26], p= <0.00001) relative to attendees of individual intervention 
(Figure 4). Meanwhile, non-commercial group attendance meant a 21% increased likelihood 
of achieving 5% weight loss (RR 1.21, 95% CI [0.95, 1.54]) relative to attendance at an 
individual intervention, but this was not significant (p= 0.11) (Figure 4). When considering only 
those studies with low risks of bias, results were similar (Figure 5). These findings support the 
conclusion that commercial group intervention is superior to individual intervention, in relation 
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to outcomes of 5% weight loss. Meanwhile, neither non-commercial group interventions nor 
individual interventions were favoured. 
 





Two studies measured likelihood of achieving more than 5% weight loss at the programme-
end time-point (Figure 6). Participants of group interventions were 57% more likely to achieve 
5% weight loss, relative to individual interventions (RR 1.57, 95% CI [1.14, 2.15], p= 0.006). 
Although these results were statistically homogenous, pre-specified sub-group analysis was 
performed by provider. Participants of commercial group interventions were 78% more likely 
to attain a 5% weight loss relative to individual interventions (RR 1.78, 95% CI [1.18, 2.69], p= 
0.006). Meanwhile, neither non-commercial nor individual intervention was favoured (RR 1.28, 
95% CI [0.77, 2.13], p= 0.34). A sensitivity analysis was not performed as the included studies 
were judged as a low risk of bias.  
 
Therefore, based on these findings from exclusively low risk of bias studies, commercial 
groups are favourable in attaining 5% weight loss outcomes relative to individual interventions. 










3.5.2 Physical Activity 
In total, 3 studies reported outcomes on physical activity levels at 1-year (Figure 7). The 
amount of time spent being physically active was a SMD 0.22 greater (95% CI -0.10, 0.54; p= 
0.19) in group compared to individual interventions. The SMD represents a small effect size 
given that is less than 0.50 (Cohen 1988). The high heterogeneity in these results was not 
dealt with by group provider sub-group analysis (p= 0.25). 
 
Figure 7: Change in Time Spent being Physically Active at 1-year (All Studies) 
 
 
The forest plot shown in Figure 8 illustrates results from 2 studies at the programme-end time 
point. Neither group nor individual intervention was favourable for physical activity levels (SMD 
0.035 95% CI [-0.17, 0.26], p= 0.66), based on moderately heterogeneous results (I2 48%, p= 
0.11). Sub-group analysis by provider did not explain heterogeneity (p= 0.26). A sensitivity 
analysis, based on risk of bias, was not performed because all studies were deemed to be at 
a low risk. 
 
Based on these results, commercial, non-commercial nor individual intervention were clinically 










3.5.3 Quality of Life 
Quality of life scores were reported by a single non-commercial intervention (Appel et al. 2011) 
at the 1-year time-point only. EQ-5D questionnaire scores were reported on the single index 
and as a visual analogue scale (VAS). The change in single index score was very marginal, 
with a 0.0004 increase (95% CI -0.03 to 0.03; p= >0.05) in the non-commercial group over the 
individual intervention.  There was a 2.35 point increase (95% CI -2.07 to 6.78) on the visual 
analogue scale in the non-commercial group compared with individual intervention. This was 
not statistically significant (p= >0.05) or clinically meaningful, given that the visual analogue 
scale is measured on a scale of 0 to 100 (Herdman et al. 2011). Therefore, there was no 
benefit in attending either a non-commercial group or an individual intervention. No 
determination can be made about commercially provided studies due to the lack of reported 
data.  
 
3.5.4 Dietary Intake 
Dietary intake was assessed by a single commercial group intervention (Jebb et al. 2011); at 
the 1-year time point only. There were significant favourable changes in nutritional intake in 
the commercial group over the individual intervention for energy intake (-181kcal, SE 81kcal, 
p=0.028), total fat intake (-9.6g, SE 4.5g, p= 0.033) and fibre intake (2.6g, SE 0.9g, p=0.016). 
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Given that most participants were female and middle-aged, these findings were thus 
compared against relevant dietary reference values (DRVs) (Department of Health 1991) and 
confirms that these findings are clinically meaningful (see  
Table 7). 
 
Table 7: Dietary Intake Compared to DRVs 
&Dietary Reference Values for 35 – 54-year-old females 
 
Although carbohydrate and sugar intake favourably decreased, this was not statistically 
significant (-14.0g, SE 9.8g, p= 0.153; -5.2g, SE 6.8g, p=0.445 respectively). However, when 
comparing the difference in sugar intake between interventions to the DRV, it is arguable that 
the sugar intake reductions are in fact clinically significant; having reduced sugar intake by a 
proportional 20% of the DRV ( 
Measure n= Difference in 
mean 
SE p value DRV Difference in DRV& 
Energy (kcal) 236 -181 81 0.028 2103 -8.6% 
Fat (g) 236 -9.6 4.5 0.033 82 -11.7% 
Carbohydrates (g) 236 -14.0 9.8 0.153 263 -5.3% 
of which Sugars (g) 236 -5.2 6.8 0.445 26 -20% 
Fibre Density (g) 236 2.6 0.1 0.016 30 +8.7% 
Measure n= Difference in 
mean 
SE p value DRV Difference in DRV& 
Energy (kcal) 236 -181 81 0.028 2103 -8.6% 
Fat (g) 236 -9.6 4.5 0.033 82 -11.7% 
Carbohydrates (g) 236 -14.0 9.8 0.153 263 -5.3% 
of which Sugars (g) 236 -5.2 6.8 0.445 26 -20% 
Fibre Density (g) 236 2.6 0.1 0.016 30 +8.7% 
Measure n= Difference in 
mean 
SE p value DRV Difference in DRV& 





These results show that commercially provided group interventions are favoured over 
individual interventions for beneficial reductions in intake of energy, fat and sugar and a 
favourable increase for the intake of fibre.  
 
These findings are limited, however, being based on only one study and, further, conclusions 
cannot be drawn for non-commercially provided group interventions due to the absence of 
reported data.  
3.5.5 Mental Health 
Changes in self-reported measures of mental health were assessed by one study (Appel et 
al. 2011) at the 1-year time point only. The mean score of depression severity increased by 
0.54 points (95% CI -0.27 to 1.36) in the non-commercial group, compared to the individual 
intervention, which was not significant (p= >0.05). Neither was this considered to be a clinically 
important score change, given that the PHQ-8 questionnaire is scored on a scale of 0 to 24 
points (Kroenke et al. 2009).  
 
Thus, based on the limited available data, neither non-commercial group nor individual 
intervention demonstrates benefit in self-reported measures of mental health. Conclusions 
could not be drawn regarding commercially provided group interventions due to the absence 
of data.  
 
Fat (g) 236 -9.6 4.5 0.033 82 -11.7% 
Carbohydrates (g) 236 -14.0 9.8 0.153 263 -5.3% 
of which Sugars (g) 236 -5.2 6.8 0.445 26 -20% 
Fibre Density (g) 236 2.6 0.1 0.016 30 +8.7% 
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3.5.6 Systolic Blood Pressure 
Five studies examined systolic blood pressure at 1-year follow-up. Analysis showed that 
systolic blood pressure reduced by -0.96mmHg (95% CI -1.83 to -0.10mmHg) and was 
statistically favourable to group over individual intervention (p= 0.03). There is minimal clinical 
importance to this change, being less than 1mmHg. What is more, these results were 
heterogeneous (I2 98%, p= <0.00001) and sub-group analysis did not explain heterogeneity 













Sensitivity analysis found a significant difference, however, between sub-groups (p= 
<0.00001) when ‘high’ or ‘unclear’ risk of bias studies were removed (Figure 10). This 
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sensitivity analysis found that commercial groups were favoured over individual interventions, 
with a change in systolic blood pressure of a marginal -0.87mmHg (95% CI -0.96mmHg to -
0.78mmHg; p= <0.00001). In contrast, individual interventions were favoured over non-
commercial group interventions. Non-commercial group interventions increased blood 
pressure by a marginal 1.00mmHg (95% CI 0.71mmHg to 1.28mmHg; p= <0.00001). Based 
on studies deemed to be at a low risk of bias, commercial and non-commercial analyses 










At the programme-end time-point, only one study reported on systolic blood pressure 
(McRobbie et al., 2016) and therefore meta-analysis was not performed. Systolic blood 
pressure increased significantly by 5.6mmHg (95% CI 1.0mmHg to 10.3mmHg; p= 0.02) in 
the group compared to individual intervention. Given that a systolic blood pressure above 
140mmHg is diagnostic for stage 1 hypertension (NICE 2011); 5.6mmHg equates to a 4% 
proportional increase which is of clinical importance.  
 
Therefore, individual intervention is clinically favoured over a non-commercial group 
intervention, but is based on limited evidence from one study. Conclusions cannot be drawn 






3.5.7 Diastolic Blood Pressure 
Five studies reported on diastolic blood pressure at 1-year (Figure 11). Blood pressure 
reduced by a clinically negligible -0.81mmHg (95% CI -1.73mmHg to 0.10mmHg; p= 
<0.00001) in group compared to individual intervention. Heterogeneity existed (I2 99%, p= 
>0.00001) and was not explained by sub-group analysis (p= 0.61).  
 
 




Performing a sensitivity analysis by including only the low risk of bias studies (Figure 12) did 
explain differences between sub-groups (p= <0.00001) and thus dealt with heterogeneity. 
Commercial groups were favoured over individual interventions (p= <0.00001) but this was 
not deemed to be clinically meaningful based on a reduction in blood pressure of 0.32mmHg 
(95% CI -0.38mmHg to -0.26mmHg). Meanwhile, neither non-commercial groups nor 
individual interventions were favoured based on an increase in blood pressure of 0.19mmHg 











Diastolic blood pressure at the programme-end was measured only by McRobbie et al. (2016), 
a non-commercial group intervention. Their results did not favour either the group or individual 
intervention (p= 0.81), with a reduction in blood pressure of 0.3mmHg (95% CI -3.0mmHg to 
2.4mmHg). Meanwhile, conclusions could not be drawn for commercial group interventions 
due to lack of data. 
 
 
3.5.8 Lipid Profile 
Overall, five meta-analyses were performed to analyse the five different reported measures of 
changes to lipid profile levels at 1-year: total cholesterol, total-to-HDL cholesterol ratio, HDL 
cholesterol, LDL cholesterol and triglycerides. No studies reported on lipid markers at the 
programme-end time point.  
 
3.5.8.1 Total Cholesterol  
Group intervention was found to reduce levels of total cholesterol by -0.03mmol/L (95% CI -
0.03mmol/L to -0.02mmol/L; p= <0.00001) based on 4 studies and findings were 
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heterogeneous (Figure 13). Sub-group analysis by group provider showed differences 
between sub-groups (p=<0.00001) which dealt with heterogeneity.  
 
Group intervention was statistically favoured when provided commercially, reducing 
cholesterol by -0.03mmol/L (95% CI -0.03mmol/L to -0.02mmol/L; p= <0.00001); albeit the 
clinical significance of this is negligible. Meanwhile, total cholesterol increased in the non-
commercial group intervention compared to individual intervention by 2.06mmol/L (95% CI 
1.82mmol/L to 2.30mmol/L; p= <0.00001) and therefore individual intervention is favoured. 
This is judged to be clinically significant given that this equates proportionally to a change of 
over half (52%) of the 4.0mmol/L optimal total cholesterol target (British Cardiac Society et al. 
2005). A sensitivity analysis, including only ‘low’ risk of bias studies, did not alter the effect 
sizes or homogeneity for either sub-group (Figure 14).  
 














At 1-year, neither group nor individual intervention was favoured according to triglyceride 
changes (-1.01mmol/L, 95% CI [-2.14, 0.12]; p= 0.08) and results were heterogeneous (I2 
99%; p= <0.00001). Sub-group analysis by group provider did not explain any differences 
between groups (p= 0.99) and thus did not address heterogeneity (Figure 15). 
 
 






Sensitivity analysis including only low risk of bias studies did address heterogeneity; but in 
turn also influenced the results of the meta-analysis (Figure 16).  
 
Results from low risk of bias studies were homogenous (I2 0%, p= 0.77). These results found 
that triglyceride levels reduced by -0.03mmol/L (95% CI -0.03mmol/L to -0.03mmol/L; p= 
<0.00001) compared to individual interventions. In the clinical context, however, this is a 
clinically negligible change. Proportionally this equates to a 2% change when compared with 
the >1.7mmol/L diagnostic for elevated triglycerides (British Cardiac Society et al. 2005).  
 
Therefore, commercial groups, non-commercial groups nor individual interventions were 
clinically favoured in relation to changes in triglyceride levels; based on low risk of bias studies.   
 
 





3.5.8.3 HDL Cholesterol  
Neither group nor individual intervention favoured changes in HDL cholesterol (0.02mmol/L, 
95% CI [-0.13, 0.18], p= 0.76) and results were homogenous (I2 0%, p= 0.99) (Figure 17). 
Sub-group analysis by provider showed no differences between commercial and non-
commercial group interventions (p= 0.94). Thus, commercial, non-commercial nor individual 
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interventions were favourable in relation to beneficial changes in HDL cholesterol levels. This 
finding was not altered by the risk of bias of the included studies as results were entirely 
homogenous.  
 




3.5.8.4 Total-to-HDL Cholesterol Ratio 
Total to HDL cholesterol ratio was reported by studies exclusively using commercial group 
providers. Results were homogenous (I2 0%, p= 0.45), regardless of risk of bias, and favoured 
group over individual intervention (-0.07, 95% CI [-0.07, -0.07], p= <0.00001) (Figure 18). The 
clinical benefit of this effect is negligible when put into context that a ratio of <4.0 is beneficial 
for cardiovascular health (British Cardiac Society et al. 2005). Based on this, neither a 
commercial group nor an individual intervention is favoured in improving total-to-HDL 
cholesterol ratio. No conclusions can be drawn about non-commercial groups due to the lack 
















3.5.8.5 LDL Cholesterol 
LDL cholesterol was measured in 2 studies which exclusively used non-commercial group 
providers (Figure 19). There were increased levels of LDL cholesterol in non-commercial 
groups (2.02mmol/L, 95% CI [1.78mmol/L, 2.26mmol/L], p= <0.00001) compared to individual 
intervention and results were homogenous (I2 0%, p= 0.92), regardless of the included studies’ 
risk of bias (Figure 19). These results indicate that individual intervention is clinically favoured 
over non-commercial group interventions in relation to changes in LDL cholesterol; when 
considered that the reference range for elevated LDL is above 2.0mmol/L, (British Cardiac 
Society et al. 2005). Due to the absence of data from commercial group interventions, 
conclusions on the effectiveness of group interventions from commercial providers cannot be 
drawn.  
 










3.5.9 Glycaemic Markers 
Three meta-analyses were performed to analyse the three different reported measures of 
diabetes disease risk at 1-year: fasting glucose, fasting insulin and HbA1c. No studies reported 
on glycaemic markers at the programme-end time point.  
 
 
3.5.9.1 Fasting Glucose 
Four studies measured fasting glucose at the 1-year time point. Group intervention was 
favoured over individual intervention (-0.05mmol/L, 95% CI [-0.05, -0.05], p= <0.00001) but 
this analysis was heterogeneous (I2 100%, p= <0.00001). Although there was a significant 
difference between the sub-groups (p= <0.00001), high levels of heterogeneity remained in 
both the commercial (I2 100%, p= <0.00001) and non-commercial (I2 95%, p= <0.00001) sub-
groups (Figure 20).  Low risk of bias sensitivity analysis did not alter these findings (Figure 
21).  
 
While these findings were statistically significant, clinically these findings have little implication 
when it is put into context that impaired fasting glucose is determined at a level of more than 
7.0mmol/L (NICE 2015). Therefore commercial group, non-commercial group nor individual 






















3.5.9.2 Fasting Insulin 
Two studies, both using commercial group interventions, reported data on fasting insulin level 
changes. Neither commercial groups nor individual interventions favoured changes in fasting 
insulin (-1.74pmol/L, 95% CI [-4.68, 1.20], p= 0.25) and results were heterogeneous (I2 100%; 
51 
 
p= <0.00001) (Figure 22). The group interventions in both included studies were provided 
commercially and therefore a sub-group analysis was not performed. 
 





Jebb et al. (2011) was the only ‘low’ risk of bias study, which on visual inspection has a much 
larger effect size on fasting insulin levels (-3.24pmol/L, 95% CI [-3.38, -3.10]). However, 
considering a fasting insulin result greater than 175pmol/L is considered elevated (Melmed 
and Williams 2011), the clinical importance of this change in fasting insulin is negligible. 
Therefore, based on one low risk of bias study, the findings are also in agreement that neither 
a commercial group nor an individual intervention is favoured in relation to changes in fasting 
insulin levels.  
 
3.5.9.3 HbA1c 
Two studies reported changes in HbA1c levels (Figure 23). Any group intervention was 
favoured over individual intervention, with statistically significant reductions in HbA1c (-
0.03mmol/mol, 95% CI [-0.04, -0.02], p= <0.00001) based on homogenous results (I2 0%, p= 
1.00). This was not clinically significant, however, given the marginal change in HbA1c level, 
when compared to the diagnostic value of 42mmol/mol given for impaired glucose tolerance 














At 1-year follow-up, all 8 studies reported attrition rates. The RR of a participant attending their 
follow-up visit was favoured by neither group nor individual intervention (RR 1.00, 95% CI 
[0.95, 1.06], p= 0.93) and results were heterogeneous (I2  50%, p= 0.02) (Figure 24).  
 
Sub-group analysis by group provider dealt with heterogeneity, finding a significant difference 
between the results of commercial and non-commercial group interventions (p= 0.002) (Figure 
24). Attendance at 1-year follow-up was favoured by neither commercial group nor individual 
intervention (RR 1.07, 95% CI [0.99, 1.16], p= 0.07). On the other hand, attendance was 7% 
less likely in a non-commercial group relative to an individual intervention (RR 0.91, 95% CI 
[0.85 0.98], p= 0.01).  
 
Performing sensitivity analysis, by including only low risk of bias studies, did alter the 
significance of these findings (Figure 25). Based on low risk of bias studies only, attendance 
was 14% more likely in commercial groups relative to individual interventions (RR 1.14, 95% 
CI [1.03, 1.25], p= 0.01). Meanwhile, neither non-commercial or individual interventions were 
favoured for attendance (RR 0.97, 95% CI [0.90, 1.04], p= 0.34). 
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At the programme-end time point, 5 studies reported attrition rates. The RR of attending at 
programme-end was favoured by neither group or individual intervention (RR 1.04, 95% CI 
[0.98, 1.09], p= 0.18) (Figure 26).  
 
Sub-group analysis by provider explained a significant difference between the results of 
commercial and non-commercial groups (p= 0.02) and dealt with heterogeneity (Figure 26).  
The RR of attendance favoured commercial group over individual intervention (RR 1.10, 95% 
CI [1.04, 1.16], p= 0.0008), but favoured neither non-commercial nor individual intervention 
(RR 0.94, 95% CI [0.83, 1.05], p= 0.27) at programme-end (Figure 26). Clinically, this is 
meaningful given that commercial group participants were 10% more likely to attend at 
programme-end, relative to individual intervention. Neither non-commercial group nor 
individual intervention participants were at a greater likelihood of attending at the programme-
end. Including only ‘low’ risk of bias studies in the sensitivity analysis did not influence these 


















3.5.11 Related Adverse Events 
The incidence of adverse events that may be related to the study interventions were reported 
as 1/662 (0.2%) in the group intervention and 0/687 in the individual intervention (0.0%). The 
SAE for this 1 participant was detailed by the authors to be a hospitalisation following 
musculoskeletal injuries. These injuries were obtained following an assault whilst exercising 
outdoors. Due to the rarity in events, meta-analysis was not possible.  
 
3.5.12 Cost-effectiveness 
Cost-effectiveness was reported by both Jebb et al. (2011) and McRobbie et al. (2016) as cost 
per QALY. In the UK, cost per QALY was far lower than the £20,000 - £30,000 NICE threshold 
and was between £8,128 (Jebb et al. 2011) to £8,439 (McRobbie et al. 2016). The costs per 
QALY were greater in other healthcare systems in Australia (£12,134) and in Germany 
(£14,416) as reported by Jebb et al. (2011). These costs are based upon imputations for the 
















3.6 Additional Sensitivity Analyses  
It was identified in section 3.4 that not all included studies in this review reported dichotomous 
data on achievement of 5% weight loss; however, 7 of the included studies had extractable 
continuous data available on absolute weight loss, measured in kilograms, at the 1-year time 
point.  
 
Results from these sensitivity analyses showed that, based on low risk of bias studies, groups 
were favoured over individual interventions; but results were highly heterogeneous (-2.22kg, 
95% CI [-2.26, -2.19], p= <0.00001; I2 98%) (Figure 28). By sub-group, commercial and non-
commercial group interventions were also favoured over individual interventions. Results were 
homogenous for commercial groups (-2.29kg, 95% CI [-2.33, -2.25], p= <0.00001; I2 0%) but 
heterogeneous for non-commercial groups (-0.62kg, 95% CI [-0.80, -0.44], p= 0.21; I2 36%).   
 
Figure 28: Sensitivity Analysis of Weight Change (kg) at 1-year (Low Risk of Bias Studies) 
 
 
Thus, sensitivity analysis confirmed that measurement of weight loss as a continuous outcome 
measure, in kilograms, did not change the direction, significance or magnitude of effect at the 





3.7 Publication Bias 
All studies reported a statistically significant p-value (<0.05) for the pre-defined primary 
outcome measure of weight change. Considering the absence of non-significant p-values that 
only one study had a smaller sample sizes (<100 participants), it is plausible that there may 
exist a potential publication bias within this review. It could be that publication is favoured by 
larger, and thus more substantially funded, studies. Moreover, it may be conceivable that 
studies with a non-significant statistical result were not published.  
 











3.8 Quality of Evidence (GRADE) 
Six outcomes were selected to be critical or important at the 1-year time point. These 
outcomes included the likelihood of a participant achieving a 5% weight loss, changes in 
systolic blood pressure, total to HDL cholesterol ratio, HbA1c and quality of life; as well cost-
effectiveness. Results of these can be found in  
Sample size Statistical Significance (p= <0.05) Total 
Significant Not significant 
≤20 - - 0 
21-100 1 - 1 
>100 7 0 7 
59 
 
   
 
3.8.1 Achieving a 5% weight loss 
The certainty in the evidence for commercial and non-commercial groups combined was 
‘moderate’. A downgrade was applied for inconsistency due to heterogeneity (I2 35%). 
Meanwhile, the certainty of evidence for non-commercial groups alone was also ‘moderate’ 
and was downgraded for imprecision due to a confidence interval which spanned a favourable  
and non-favourable effect. The certainty of the evidence for commercial groups was ‘high’ as 
no downgrade was applied. In-directly comparing commercial to non-commercial group 
interventions showed clinically very important findings based on ‘moderate’ to ‘high’ quality 
evidence. Out of 1,000 participants, 217 more participants would lose 5% weight in a 
commercial group programme relative to an individual intervention. Meanwhile, 59 more 
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MD 0.0004 EQ-5D score (0.03 lower to 0.03 higher). MD 2.35 EQ-5D VAS score 
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HIGH 
ICER for group intervention over individual intervention in the UK according to 




participants out of 1,000 would lose 5% weight loss in a non-commercial programme, relative 
to an individual intervention.  
 
3.8.2 Systolic Blood Pressure 
Changes in systolic blood pressure were clinically marginal and thus neither group nor 
individual intervention was favoured regarding changes in systolic blood pressure. Several 
downgrades were applied to the quality of the evidence and was deemed to be of ‘very low’ 
quality. Inconsistency was downgraded twice, being ‘very serious’, due to heterogeneity being 
confirmed by both I2 (99%) and p-value (<0.00001). The certainty of indirectness was 
downgraded to ‘serious’ because of this measure being a surrogate marker for risk of 
cardiovascular disease. There was also ‘serious’ imprecision because of the wide interval of 
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not serious not serious not serious None ⨁⨁⨁⨁ 
HIGH 
ICER for group intervention over individual intervention in the UK according to 
2016 financial year calculations is £8,128 - £8,439 
- 
Table 9: GRADE Assessment and Summary of Findings 
 
Explanations: a I2 suggests heterogeneity (greater than0%), b p-value suggests heterogeneity (greater than0.05), c surrogate marker, d very small sample size (n= <100), e small 




When considering evidence from non-commercial group intervention providers and 
commercial group providers as separate interventional approaches, neither group nor 
individual intervention from either provider was favoured. This is due to the clinically marginally 
changes in systolic blood pressure. The quality of evidence for both commercial and non-
commercial groups was ‘moderate’, with one downgrade being applied to both for indirectness. 
This downgrade was assigned because systolic blood pressure is a surrogate marker of 
cardiovascular disease risk.  
 
3.8.3 Total to HDL Cholesterol Ratio 
The quality of the evidence for this outcome was downgraded to ‘moderate’ since this is a 
surrogate marker of cardiovascular risk. Results from commercial and non-commercial groups 
were included together and thus this evidence is applicable to any group intervention. 
Changes in total to HDL cholesterol ratio were not clinically superior in group or individual 
intervention. Based on this ‘moderate’ quality of evidence, neither group nor individual 
intervention was favoured in regard to clinical changes in total to HDL cholesterol ratio.  
 
3.8.4 HbA1c 
Clinically, changes in HbA1c favoured neither any group nor an individual intervention. The 
quality of evidence for this outcome is ‘moderate’, downgraded due to imprecision because of 
a small sample size of 76 participants.  
 
3.8.5 Quality of Life 
The risk of bias for evidence of quality of life is ‘low’, albeit based upon one study. Several 
certainty downgrades were applied to this outcome, including one downgrade for the 
indirectness of questionnaire assessment and two downgrades for imprecision; due a small 
sample size of n= 277, and confidence intervals that spanned favourable and non-favourable 
findings for the EQ-5D VAS scores. Clinically, due to marginal changes in quality of life, neither 
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a non-commercial group nor an individual intervention was favoured based upon the ‘low’ 
certainty of evidence. 
 
3.8.6 Cost-effectiveness 
No downgrades were applied to the quality of evidence for the outcome of cost-effectiveness. 
There is, therefore, ‘high’ certainty evidence to suggest that both commercial and non-
commercial group interventions are equally cost-effective when compared to individual 
intervention, with a cost per QALY of £8,128 and £8,439 for commercial and non-commercial 








4.0 Discussion  
4.1 Summary of Key Findings  
This systematic review was conducted with the purpose of investigating the efficacy of group 
relative to individual lifestyle interventions for adult weight management. There is sufficiently 
robust evidence from important measures (5% weight loss attainment, cost-effectiveness and 
changes in HbA1c, systolic blood pressure and total:HDL cholesterol) to determine the efficacy 
of commercial groups and non-commercial groups at 1-year, compared to individual 
interventions. It was not possible to determine efficacy according to patient-reported outcome 
measures, including quality of life, as there was insufficient data available (refer to section 
3.4). 
4.1.1 Commercial Groups versus Individual Interventions 
There is a ‘high’ certainty in the evidence that commercial group interventions are favourable 
over individual interventions in inducing a clinically meaningful 5% weight loss at 1-year. In 
context, per 1,000 service users referred for weight management intervention, 217 more 
service users will achieve 5% weight loss in a commercial group, then in an individual 
intervention. In other words, according to number needed to treat (NNT) analysis, 1 in 6 
service users (95% CI 1 in 4.4 to 8.2) will achieve 5% weight loss by attending a commercial 
group. The certainty of the evidence was also ‘high’ to suggest that commercial group 
interventions are cost-effective when considered against the nominal cost-per-QALY threshold 
(Appleby et al. 2007). 
 
Superiority in weight loss did not translate into any clinical reduction in risk of cardiovascular 
disease or diabetes at 1-year, however. There is ‘moderate’ certainty that neither individual 
nor commercial group interventions led to any clinical improvement in measures of systolic 




4.1.2 Non-Commercial Groups versus Individual Interventions 
There is ‘moderate’ certainty that indicates a that there was favourability in neither non-
commercial groups or individual interventions for the attainment of 5% weight loss; although 
this is not conclusive. The wide confidence interval suggests that after 1-year, per 1,000 
service users, 59 more service users would achieve 5% weight loss in the non-commercial 
group, compared to individual intervention. However, this risk difference was inconclusive 
based on a confidence interval whereby anywhere between 14 fewer to 151 more service 
users would achieve this outcome. NNT was not calculated for non-commercial groups due to 
the absence of statistical significance.  
 
There was ‘moderate’ certainty in the evidence that there are ambivalent changes to markers 
of cardiovascular disease and diabetes control, showing no clinical improvements or detriment 
to total:HDL cholesterol, systolic blood pressure or HbA1c as a result of a non-commercial 
group compared to individual intervention. 
 
There is ‘high’ certainty that non-commercial group interventions are cost-effective, according 
to NICE thresholds (Appleby et al. 2007). In fact, commercial and non-commercial group 
interventions are equally cost-effective.  
 
4.2 Strengths and Limitations  
4.2.1 Methodological Rigor  
This systematic review followed a protocol that was made publicly available online on the 
PROSPERO website (Abbott and Bryant 2017), prior to the literature searches being 
undertaken. Thus, this deters a reporting bias towards significant findings and ensures 
protocol fidelity. However, the absence of any gender data in the included studies meant that 
the planned sub-group analysis on gender was omitted. This represents an addendum from 
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the published protocol. This protocol amendment has been recorded electronically on 
PROSPERO for audit purposes and is fully transparent and justified. 
 
The search strategy was designed alongside a subject-expert librarian and followed the ‘Highly 
Sensitive Search Strategy’ used by the Cochrane Collaboration (Glanville et al. 2006). In 
addition, to ensure the search was sensitive and thus maximising the yield of relevant studies, 
comprehensive MeSH and keyword search terms were used. The search strategies were 
applied to multiple healthcare-orientated databases, thus reducing the risk of introducing a 
database bias. However, the literature search did rely solely on database searching and did 
not use other possible sources, such as hand-searching relevant journals; and therefore 
source selection bias cannot be ruled out.  
 
The clearly defined research question led to detailed criteria for inclusion and exclusion, which 
were used to accept or reject studies for inclusion as part of the screening process. Screening 
was conducted by two reviewers, who were blinded to each other’s decisions until the point of 
arbitration. Using at least two reviewers reduces the possibility that relevant literature will be 
discarded (Edwards et al. 2002) and reduces the risk of selection bias. Further, data extraction 
was peer reviewed to minimise data errors. The agreement between reviewers was not 
quantified, however, and it may have been useful to use kappa statistics (Hedges and Cooper 
1994) to measure inter-rater reliability. 
 
Further, the reporting on this review followed the evidence-based items for reporting in 
systematic reviews, as outlined by Moher et al. (2009). This provides transparency and detail 




4.2.2 Generalisability  
Careful consideration was given to the specification of the inclusion criteria for the review, in 
order to ensure that the review could be generalised to overweight and obese adults across 
populations. The inclusion criteria for the intervention setting included any non-inpatient 
settings and these were not restricted to specific countries.  
 
The population sample within this review included a substantial sample size of 2,139 
participants.  Interventions predominately took place in the United Kingdom and, as well, were 
delivered in other westernised countries: United States of America, Spain, Australia and 
Germany. The setting of intervention was varied across outpatient, primary care and 
community settings. Moreover, recruitment was pre-dominantly multi-centred and therefore 
the population within this review is believed to be statistically representative of, and 
generalisable to, a large westernised population.  
 
Despite inconsistency in the models and programme design of the commercial- and non-
commercial groups, results were overall homogenous within each category. The inconsistency 
in intervention designs is reflective of the diversity in the design of lifestyle interventions 
internationally. In this, these results are not limited to a specific model of intervention and can 
be generalisable to commercial or a non-commercial lifestyle group intervention as separate 
entities; regardless of how they are delivered in practice.  
 
There was no time exclusion for publication within this review; as lifestyle interventions for 
overweight and obesity are not novel to modern day. All studies were undertaken post-
millennial with the exception of Long et al. (1983). It could, however, be argued that since the 
1980’s the scale and demographic of the overweight and obese population has changed, and 




4.2.3 Applicability  
The explicit research question and inclusion asked in this review allows any reader to establish 
the applicability of this review to their own population group. In relation to practice in the UK, 
this review is highly applicable.  
 
The demographic of the participants included in this review mirror that of the weight 
management referral criteria for Tier 2 and Tier 3 services in the UK. Participants within this 
review were towards middle-age (mean 47 years old), obese (mean BMI 35.5kg/m2) and the 
majority were female (67.3%). In context, the demographics of participants of Tier 3 weight 
management are also the majority female (71%), aged 45-64 years old (45.1%) and have a 
BMI of 35-40kg/m2 (35.4%) (Blane et al. 2017). This demographic is echoed by (Ahern et al. 
2016) for Tier 2 service users, whereby service users are on average 53 years old, have a 
BMI of 34.5kg/m2 and are 67.9% female.   
 
In clinical practice, Tier 2 and Tier 3 services are funded by local authorities and clinical 
commissioning groups; thus are not centrally funded. The provisions of these services are 
highly variable and 40% of CCGs and local authorities in England do not commission such 
services (Coulton et al. 2015). This ‘postcode lottery’ means that NHS-funded interventions 
for overweight and obesity are not always accessible to service users, and therefore may not 
be a viable treatment option. Therefore, although this research suggests that commercial 
group interventions are the most effective treatment option for weight loss, these may not 
funded through primary care referral and therefore access may only be possible via the service 
users’ self-funding.   
 
4.2.4 Outcome Measures 
International obesity guidelines recommend a weight loss of 5% to achieve improvements in 
health outcomes (Jensen et al. 2014, NICE 2014a). Thus, this review measured arbitrary 
achievement of 5% weight loss in order to directly establish clinical efficacy.  Only 5 of the 8 
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studies reported on proportional weight loss in this way. Attempts were made to provide more 
complete data by conducting a sensitivity analysis using the weight change data reported in 
kilograms. This sensitivity analysis contained the usable data from 7 of the 8 studies. 
Measuring absolute, as opposed to proportional, weight loss did not alter the direction, 
significance or magnitude of effect.  This demonstrates that the observed outcomes for 
achievements in 5% weight loss are robust, regardless of the unit of measurement used.  
 
Many of the clinical outcomes measured in this review were surrogate markers and therefore 
cannot definitively ascertain diabetes and cardiovascular disease risk. Moreover, even after 
sub-group and sensitivity analyses were performed, significant heterogeneity remained for 
blood pressure. This may suggest that there were other factors that could explain the variance; 
or it could be a reflection of the methodological rigor in which these measurements were 
obtained.  
 
IPAQ was the sole measure of physical activity used by the included studies in this review. 
IPAQ is not validated as an outcome measurement for interventional studies; give that there 
is lack of evidence that IPAQ is responsive to change in physical activities. Therefore, these 
results may not be valid (Bauman et al. 2009). Considering this, however, this unit of measure 
is the most feasible and practical to administer in the context of interventional studies; 
particularly those with larger sample sizes. 
 
While physical activity was uniformly measured across included studies using IPAQ; selective 
reporting of the IPAQ domains meant that there was no consistency in measure. To enable 
this data to be used for the meta-analysis, standardised mean difference (SMD) was used as 
a summary statistic. However, this analysis leads to difficulty in clinical interpretation; as the 




4.2.5 Data Imputations  
BOCF data was extracted a priori as it is viewed to be more methodologically robust than 
completers-only data (Cresswell and Mander 2014). Nevertheless, the validity of this approach 
for obesity interventions is debatable. In practice, the BOCF approach is highly conservative 
considering that some participants may regain an excess of the weight lost, after completing 
their treatment (Ware 2003). Where only completers-only data was available, this was 
included in the meta-analyses in order to not exclude otherwise eligible studies. It is 
acknowledged, however, that meta-analysis results may differ according to the missing data 
assumptions of included studies (Cresswell and Mander, 2014). Sensitivity analysis according 
to risk of bias addressed this. The Cochrane Risk of Bias Tool includes an assessment of the 
handling of missing data to determine attrition bias. Studies in this review were judged to have 
a ‘high’ risk of bias for the attrition bias domain if missing data imputations were not performed. 
Therefore, the risk of bias sensitivity analyses within this review provides evidence that 
combining data from studies with and without imputations did not influence the direction or 
size of effect.  
 
4.2.6 Publication Bias 
While not applying a language restriction to the article inclusion criteria meant screening was 
required translation and thus added labour, this did reduce language bias. The included 
articles in this review were all written in the English language which may reflect the lingua 
franca of global science; but this does not mean one should assume that all important research 
is available in English (Amano et al. 2016). We did not carry out searches of non-English 
language dominated databases, such as SciELO, and therefore our included studies are 
biased towards abstracts published in English.  
 
Publication bias was minimised further by searching the ISRCTN database and permitting 
inclusion of grey literature. Despite this, only one conference proceeding was included as a 
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linked article to the Jebb et al. (2011) study. Further, some grey literature was excluded as 
their eligibility was inconclusive and authors did not respond to information requests.  
 
There is indirect evidence of publication bias, given that all but one study was a large study 
and all reported significant findings. Only observational evidence of publication bias was able 
to be performed, owing to an insufficient number of studies to test for publication bias through 
funnel plot asymmetry. Publication bias towards larger studies is not necessarily a limitation, 
given that larger trials tend to have greater methodological rigor (Egger et al. 2003). Further, 
the dominance of large studies in this review means that the issue of small study effects and 
overestimation of effect sizes is minimised.  
 
4.2.7 Intervention Components 
This review did not seek to identify which intervention components contributed to efficacy and 
therefore meta-regression analyses were not performed. Therefore, while this review has 
firmly established that commercial-group interventions are more effective than individual 
interventions, it is not clear why.  
 
This review hypothesised that group interventions would be more effective than individual 
interventions. It is believed that group lifestyle interventions provide peer support which can, 
in turn, modify the participant’s social network (Christakis and Fowler 2007). In this sense, 
network phenomena and social influence can spread positive weight management and health 
behaviours between those attending interventions for overweight or obesity.  
 
The findings of this review support this as a possible hypothesis, given that all group 
interventions included in this review demonstrated the interventionist delivering the ‘social 
support’ behavioural taxonomy (Michie et al. 2013) and thus implies the enactment of 
‘Buddying Support’, ‘Motivational Support’ and ‘Imitation Modelling’ behaviours; according to 




It is arguable, however, that the treatment effect may not be due to peer support, rather it may 
be due to intervention intensity. Research has shown that greater weight loss during lifestyle 
interventions is associated with higher contact time or frequency of contacts per participant 
(Greaves et al. 2011). As well as providing more frequent contact, group interventions included 
in this review provided more hours of contact per participant (range of 12 to 55 hours) 
compared to individual interventions (range of 2.5 to 11 hours). It is therefore a plausible 
hypothesis that group interventions could be more effective owing to their time-efficiency 
thereby providing greater interventionist contact time per participant.  
 
4.3 Comparison with Other Systematic Reviews 
This systematic review is compared with existing systematic reviews that have directly or in-
directly evaluated the efficacy of group-based compared to individually delivered lifestyle 
interventions for overweight and obese adults.   
 
4.3.1 Direct Comparisons  
The systematic review by Paul-Ebhohimhen and Avenell (2009) provided a direct comparison 
between group and individual interventions. This systematic review paper included citations 
from two combined published reviews (Avenell et al. 2004, (Paul-Ebhohimhen and Avenell 
2008). These citations were obtained using a broad search strategy and included studies up 
to 2001 (Avenell et al. 2004) and added to by citation alerts for some, but not all databases, 
to the year 2008. Further, journals were hand-searched specifically for financial reward 
interventions (Paul-Ebhohimhen and Avenell 2008). The limitations of this broad search 
strategy meant that there was poor reliability in the results. Reliability was limited by the 
inclusion of predominately small studies which were dominated by a female population. 
Moreover, their review lacked recent data; including only one study published after 1986. 
Applicability of the pooled results to the general overweight and obese population is also 
limited, given the generally low attrition rates which were as low as 3.4 to 18%. Further, Paul-
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Ebhohimhen and Avenell (2009) collected anthropometric data only. The authors had planned 
to conduct cost-effectiveness analyses; however this was not possible owing to insufficient 
data. Their lack of outcome data on cost-efficacy is not surprising given that pre-millennial, 
conducting cost-effectiveness analysis to establish the ‘value for money’ of medical 
interventions was not established as an objective method (Kirkdale et al. 2010). 
 
In addition, the authors did not extract data on proportional weight loss. However, Paul-
Ebhohimhen and Avenell (2009) did report summary estimates on weight loss, expressed as 
an absolute weight loss in kilograms. Results from their meta-analysis of 11 intervention 
groups showed homogenous findings that group interventions led to a significantly greater 
weight loss (p= 0.03) at one year, when compared with individual treatment (-1.4kg, 95% CI -
2.7kg to -0.1kg). Comparing their results with our sensitivity analysis of 7 intervention groups 
shows that our results were similar. Albeit, our findings favoured group over individual 
interventions with more significance (p= <0.00001). Moreover, we found participants lost 
nearly a further kilogram more than participants in the Ebhohimhen and Avenell (2009) study. 
Our findings also had a greater degree of precision, with a narrower confidence interval (-
2.32kg, 95% CI -2.26kg to -2.19kg). However, our results were highly heterogeneous, even 
when based on low risk of bias studies (I2 98%).  
 
Therefore, our review provides an up-to date, and arguably more holistic, examination of 
efficacy beyond anthropometry alone and we provided a cost-effectiveness analysis to inform 
policy. In comparison, all but one of the studies in our review were large studies, mixed-gender 
and published post-millennial (2001 to 2016) which is owed to our more robust methodology. 
Further, the differences in methodologies between our studies explains why, despite having 
similar research questions and inclusion/exclusion criteria, our review included only one 




4.3.2 Indirect Comparisons 
Systematic reviews of RCTs with head-to-head direct comparisons, such as Paul-Ebhohimhen 
and Avenell (2009) and our own review, reduce the potential influence of confounders that 
may contribute to differences in effect; by ensuring participants are randomised using the 
same criteria. However, systematic reviews with indirect comparisons can include a wider pool 
of evidence and therefore also have their place.  
 
Hartmann-Boyce and colleagues produced two such systematic reviews which provided in-
direct comparisons between group and individual interventions (Hartmann-Boyce et al. 2014a) 
and between commercial and primary-care delivered interventions (Hartmann-Boyce et al. 
2014b).  
 
The primary outcome for both studies was absolute weight loss, measured in kilograms.  The 
authors acknowledged that the power of their reviews to detect changes in secondary 
outcomes, such as blood pressure, lipid profile and fasting glucose, was limited due to a lack 
of data reporting. Our study has provided more power to detect changes in some, but not all, 
of these secondary outcomes given that our literature search identified more recent studies 
(up to 2016), compared to Hartmann-Boyce and colleagues reviews whose included studies 
were up to 2012. Like our review, however, Hartmann-Boyce and colleagues found insufficient 
evidence on quality of life or mental health. Further, like us, they found no evidence that 
programmes led to adverse events.   
 
Hartmann-Boyce and colleagues used a consistent approach to outcome data collection using 
BOCF as a means of imputation for all studies, as described by Kaiser et al. (2012). This 
provides a conservative estimate suitable for assessing the benefit to the obese population. It 
was not possible to use this method in our review, as our primary outcome examined 
proportional, rather than absolute, weight loss. In addition, and likewise to our methods, 
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Hartmann-Boyce and colleagues conducted sensitivity analysis using only complete-case 
data; which also showed similar results.  
  
Hartmann-Boyce et al. (2014a) conducted meta-regression analyses to examine the 
characteristics of lifestyle interventions that determine efficacy in weight loss, measured in 
kilograms. While we did not perform regression analyses in our review, we can draw 
associations between the results from Hartmann-Boyce et al. (2014a) and our own. However, 
it should be reiterated that the results from Hartmann-Boyce et al. (2014a) are based on in-
direct comparisons and therefore are not an exact comparison to our own study.  
 
The regression analyses performed were of the delivery method, as categorised by group or 
individual. Sixteen interventions were delivered by group sessions while 21 were delivered via 
individual sessions. Neither group (0.4kg, 95% CI -1.6 to 2.3kg, p=0.71) nor individually (-
0.4kg, 95% CI -1.9 to 2.0kg, p=0.97) delivered interventions were found to be significant 
contributors to weight loss efficacy. These results differ from our findings which, based on a 
direct comparison, found that group interventions were significantly favoured over individual 
interventions (p= <0.00001); albeit based upon heterogeneous results. Heterogeneity in our 
study was then explained by provider sub-group analysis. Hartmann-Boyce et al. (2014a) did 
not analyse commercial and non-commercial groups as separate entities and therefore 
comparisons cannot be made in this regard.  
 
Regression analyses were also performed according to behavioural taxonomy, as categorised 
by CALOR-E (Michie et al. 2013); finding that only the ‘comparison of behaviour’ was 
associated with greater weight loss in kilograms (-1.5kg, 95% CI -2.9 to -0.1kg, p= 0.032). 
Meanwhile, the ‘social support’ taxonomy was not associated with weight change (0.5kg, 95% 
CI -0.6 to 1.6kg, p= 0.360). Results from their regression analysis do not support our 
hypothesis that the ‘social support’ taxonomy could explain the greater efficacy of group 
interventions. However, 5 of the 12 group interventions included in our review were also 
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identified to use the ‘comparison on behaviour’ taxonomy. Interestingly, this taxonomy is a 
consistent component of the ‘WeightWatchers’ commercial group programme. Thus, this 
raises an alternative underpinning that participants are motivated by comparing their 
behaviour, or weight loss results, with their peers; driving further weight loss or maintenance. 
 
It should be reiterated that these comparisons should be interpreted with caution. In-direct 
comparisons lose the power of randomisation and are likely to be biased (Bucher et al. 1997). 
 
A further study, by Hartmann-Boyce et al. (2014b), performed meta-analyses sub-grouped by 
intervention provider. They categorised interventions as commercial (group-delivered) or 
primary-care (individual- or group-delivered). The results from the primary-care sub-group 
analyses were not exclusively individual interventions and therefore are irrelevant to our 
review and will not be discussed. The commercial sub-group, on the other hand, is relevant. 
 
Their commercial sub-group included 5 commercial group programmes. Results from their 
meta-analysis showed that commercial interventions are effective compared to minimal 
intervention; yielding a mean difference of -2.22kg (95% CI -2.89kg to -1.54kg). All included 
studies were common with the commercial studies included in our review (Heshka et al. 2003; 
Jolly et al. 2011; Jebb et al. 2011). Our study compared against an active individual 
intervention. We found that commercial group interventions were equally significant (p= 
<0.00001).  Findings from our sensitivity analysis using absolute weight loss, found a similar 
mean weight loss of -2.29kg (95% CI -2.33 to 2.25kg), but this was not identical. Further, our 
results were entirely homogenous (I2 0%) while heterogeneity remained (I2 20%) in findings 
by Hartmann-Boyce et al. (2014b). These discrepancies are because of our systematic review 
directly comparing with an active individual intervention rather than against a minimal 





5.0 Conclusions  
This is the first systematic review for nearly a decade to directly determine the effectiveness 
of group compared to individual lifestyle interventions. This research has added new 
knowledge, determining that commercialised group programmes have a profound and 
beneficial influence on weight loss efficacy. The implications for practice have been 
considered below in context for service users, clinicians and policy makers in the UK; given 
that this was the dominant setting for the studies included within this review. However, it should 
be noted that this review is also generalisable to other westernised populations.  
 
5.1 For Service users   
Adult service users who are overweight or obese should speak with their primary care provider 
to establish which lifestyle interventions are available to them, as there is substantial 
geographical variation in access. If a service user has access to several options, the findings 
of this review suggest that service users should choose a commercial group over a non-
commercial group or individual intervention.  
 
Service users should not be discouraged, however, if commercial group interventions are not 
available to them through the NHS. This review found that non-commercial group and 
individual interventions also led to weight loss, albeit less significant. What is more, group 
interventions may not be suited to all service users; including service users suffering from 
agoraphobia or social anxiety, or service users requiring translator services. 
 
Service users tend to place priority on quality of life outcomes, particularly outcomes related 
to emotional and psychological functioning, when considering the efficacy of treatment options 
(Janse et al. 2004). Whilst we pre-specified quality of life and mental health as secondary 
outcomes in this review, there was insufficient evidence available to determine effectiveness 




While the interventions included in this review induced weight loss, no other clinical benefit 
was seen. Therefore, service users should be realistic about the health improvements that 
they will see from a lifestyle intervention alone over a 1-year period. Considering this, service 
users with co-morbidities should be open to pharmacological and/or surgical interventions as 
concomitant treatment alongside lifestyle intervention. 
 
5.2 For Clinicians    
Current NICE guidance (NICE 2014a) are limited in their interpretation for lifestyle 
interventions. The knowledge that this present systematic review contributes will compliment 
NICE guidance by providing more detailed and practical information to help clinicians consider 
the most effective modality of lifestyle intervention for their service users.  
 
The evidence from this review suggests that clinicians should favour referral to a group rather 
than individual lifestyle intervention. More specifically, this evidence suggests that clinicians 
in primary care should consider referral to commercial over non-commercial group 
intervention; if the option is available. This supports previous research that has shown that 
referral to commercial weight management services from primary care are suitable, practical 
and effective (Lewis et al. 2013; Aveyard et al. 2016).  
 
While the evidence from this review concludes that commercial group interventions are the 
most effective treatment modality for the general population, the individual service user 
presenting in clinical practice may not feel this option is suited to them. Treatment should be 
a shared decision-making process and service users’ choices should be exercised to promote 




5.3 For Policy Makers    
Even though this review concluded with high certainty that commercial group interventions are 
shown to be more effective in attaining a clinically important 5% weight loss, policy makers 
will ultimately make their decisions based on cost-effectiveness. The evidence from this review 
has demonstrated that both commercial and non-commercial group interventions are cost-
effective by cost per QALY, according to NICE thresholds (Appleby et al. 2007).  
 
Commissioners are likely to prioritise cost per QALY gained in order to maximise health gain 
for the whole population. Given that obesity is a public health epidemic, the commissioning 
priority may be to reduce health inequalities across the population. In this case, commissioners 
may value a cost-consequence analysis to base their decision-making (NICE 2011b); which 






6.0 Future Research  
The implication of this systematic review in guiding future research has highlighted the need 
for weight management interventions to report to a core outcome set. While at present a core 
outcome set does not exist, partly because of the complexity and variability of intervention 
targets, national guidance frameworks do exist on minimal outcome reporting i.e. the Standard 
Evaluation Framework for Weight Management Interventions (Ells et al. 2018; updated from 
Roberts et al. 2012). In order to enhance the comparability and synthesis of future studies, 
future empirical studies should follow guidance on the minimal outcome reporting 
recommendations.   
 
Given that obesity is a chronic condition and weight maintenance after initial weight loss is a 
challenge, RCTs with prolonged follow-up are required to establish efficacy in the longer-term.  
Future RCTs should also consider reporting proportional weight loss, such as achievement of 
5% weight loss, in order to provide more clinically relevant data. Including economic analyses 
in future studies will increase the evidence base on cost-effectiveness and will be necessary 
to enable clinicians and policy makers to manage service provision and make the best use of 
resources. Further, there is a need for greater emphasis on patient-reported outcome 
measures to assess efficacy based on service users’ concerns; rather than focusing on the 
clinical outcomes believed to be prudent to researchers.   
 
This systematic review did not directly compare the efficacy of commercial and non-
commercial group interventions with each other. A future RCT comparing these two 
intervention providers, with equal time and contact intensity, would be the means to find a 
definitive answer as to whether commercial group-interventions are truly more effective than 




Moreover, further research could also seek to identify interventional components that 
determine commercial group interventions to be more effective. This knowledge would enable 
replication in non-commercial led group interventions.  
 
On the other hand, this review has established with ‘high’ certainty that commercial group 
interventions are superior for weight loss, as opposed to individual interventions. This review 
has also provided in-direct evidence that commercial group interventions are equally as cost-
effective as, and more widely accessible than, non-commercial group interventions.  
 
Therefore, I would raise the question as to whether the cost of further research is even 
warranted or justified. Rather, this review may provide sufficient evidence to convince policy 
makers that the first-line lifestyle intervention for adults with overweight and obesity should be 
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mean1  mean2  mean12 =((C60*C61)+(E60*E61))/I61 
n1  n2  n12 =C61+E61 
sd1  sd2  sd12 =SQRT(I63) 


































p-value Mean Difference 
(£) (year) b 
p-value 
Jebb Australia 243 0.021  0.006 228 (2011) - 12,143  
Germany 238 0.009  0.222 116 (2011) - 14,416 
UK 178 0.015  0.033 109 (2011) - 8,128  
McRobbie UK 179 0.0104 0.088 81 (2012) 0.787 8,439  
 
 
Converted into estimated cost for 2016 according to Bank of England inflation rate using the 
Bank of England online ‘Inflation Calculator’. Available from: 
https://www.bankofengland.co.uk/monetary-policy/inflation [2 February 2018] 
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